Zobrazeno 1 - 10
of 89
pro vyhledávání: '"B. Vaughan Hudson"'
Publikováno v:
European Journal of Cancer. 36:384-389
The prognosis of Hodgkin's disease (HD) has improved during the last 30 years. This study was planned to analyse long-term survival of HD patients and to compare survival rates estimated from clinical trials and population-based data. Individual data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b522db8f26355e3ff9f98afba23e1795
https://doi.org/10.1016/s0959-8049(99)00267-1
https://doi.org/10.1016/s0959-8049(99)00267-1
Autor:
Walter M Gregory, J. K. Wood, Adrian C. Newland, Peter Hoskin, K. A. MacLennan, Donald Milligan, Paul Smith, David C. Linch, G. Vaughan Hudson, B. Vaughan Hudson, David Cunningham, P. A. Stevenson, Barry W. Hancock
Publikováno v:
Annals of Oncology. 11:S87-S90
Background: Between 1987 and 1991, the British National Lymphoma Investigation randomized 459 patients with non-Hodgkin's lymphoma with a large-cell component to either CHOP or the PACEBOM regimen. Patients and methods: Four hundred fifty-nine eligib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ecf1122c4eba9715e648286485c417a
https://doi.org/10.1093/annonc/11.suppl_1.s87
https://doi.org/10.1093/annonc/11.suppl_1.s87
Autor:
L Anderson, KA MacLennan, D Mason, B. Vaughan Hudson, M Burke, G. Vaughan Hudson, Peter Selby, ME Hill, David C. Linch, Paul A. Clarke, David Cunningham, F Di Stefano
Publikováno v:
Europe PubMed Central
The Bcl-2 protein is capable of preventing apoptosis, and in vitro evidence suggests a role in drug resistance. It is expressed and the gene is rearranged in a proportion of cases of large-cell non-Hodgkin's lymphoma (NHL), but the clinical significa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be11c3c55bade80891fe11d1542096ed
https://doi.org/10.1182/blood.v88.3.1046.1046
https://doi.org/10.1182/blood.v88.3.1046.1046
Autor:
Donald Milligan, P Hoskin, David C. Linch, G. Vaughan Hudson, Barry W. Hancock, L Anderson, B. Vaughan Hudson, P. A. Stevenson, Adrian C. Newland, K. A. MacLennan, David Cunningham, J. K. Wood, Walter M Gregory
Publikováno v:
British Journal of Cancer
A combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a standard therapy for histologically aggressive non-Hodgkin's lymphomas for over 20 years, but several newer regimens, referred to as second or third genera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93bf390bbe7b7512e658d3eb01d0dc7b
http://europepmc.org/articles/PMC2074593
http://europepmc.org/articles/PMC2074593
Publikováno v:
British Journal of Cancer
A retrospective analysis was performed of 451 adult patients with clinical stage 1/1E non-Hodgkin's lymphoma treated initially with radiotherapy alone. Histopathologically 208 patients had low-grade disease and 243 patients high-grade disease. The co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d83cf50edb8e47de909d42cbf9a74e
http://europepmc.org/articles/PMC1969460
http://europepmc.org/articles/PMC1969460
Publikováno v:
British Journal of Cancer
The risks of second primary cancer were analysed in 2846 patients with Hodgkin's disease treated within the British National Lymphoma Investigation during 1970-87. The relative risk (RR) of leukaemia was significantly greater in women (RR = 30.1; 95%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12bd4d577f5b9f20a0193e6007fa0392
https://doi.org/10.1038/bjc.1993.470
https://doi.org/10.1038/bjc.1993.470
Publikováno v:
British Journal of Cancer
Records of 2,145 cases of Hodgkin's disease in England and Wales treated by the British National Lymphoma Investigation during 1970-84 were sought in the national and regional cancer registers. One thousand eight hundred and eight-six (88%) were reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4fc13de77a5f52a89a16bd5e5399d8
https://doi.org/10.1038/bjc.1993.60
https://doi.org/10.1038/bjc.1993.60
Publikováno v:
Hematological Oncology. 10:81-86
The British National Lymphoma Investigation (BNLI) has assessed the use of an IMVP-16 regimen (ifosfamide, methotrexate, VP-16) in 46 patients with high grade non-Hodgkin's lymphoma (NHL) who on first-line chemotherapy either failed to attain a compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::333df0fcf28dc931e41be51fffda1898
https://doi.org/10.1002/hon.2900100203
https://doi.org/10.1002/hon.2900100203
Autor:
K. A. MacLennan, A.M. Jelliffe, G. Vaughan Hudson, J.L. Haybittle, B. Vaughan Hudson, M.H. Bennett, Barry W. Hancock
Publikováno v:
British Journal of Cancer
From 1979-1983, 299 patients with stage III or IV Hodgkin's disease (HD) were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran substituted for mustine). Two hundred and ninety patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f61083a529f137f235cd69f953294e0
https://doi.org/10.1038/bjc.1991.134
https://doi.org/10.1038/bjc.1991.134
Publikováno v:
Annals of Oncology. 2:83-92
Twenty-two of 3033 patients with Hodgkin’s disease (HD) randomised into the clinical trials of the BNLI have developed non-Hodgkin’s lymphomas (NHLs) at periods up to 16 years after presentation (1 simultaneous and 1 composite), giving an inciden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5991f485e986afea65ae24f587c5948f
https://doi.org/10.1093/annonc/2.suppl_2.83
https://doi.org/10.1093/annonc/2.suppl_2.83